Biopharmaceutical Company Hisun Borui Got Strategic Investment from PAG

According to Pedaily, Zhejiang Hisun Pharmaceutical co., LTD. (Hisun PharmaceuticaL) and Pacific Alliance Group (PAG ) jointly announced that Zhejiang Hisun Borui Biopharmaceutical co., LTD. (Hisun Borui), a subsidiary of Hisun Pharmaceutical, formally introduced PAG as a strategic investor.

Currently, PAG has signed a final agreement with Hisun Pharmaceutical to acquire the majority share of Hisun Borui. PAG will pay about 3.828 billion yuan for a 58% stake in Hisun Borui, while Hisun Pharmaceutical will retain 42%. The deal would be the largest private equity investment in China's biotechnology industry to date.

Established in January 2019, Hisun Borui is the research, production and marketing platform of monoclonal antibody biological drugs, which are the major products of Hisun Pharmaceutical. Hisun Pharmaceutical started the business of biological drugs in 2003. Hisun Borui has established a rich pipeline of biological drugs in the fields of autoimmunity and tumor treatment.

Hisun Borui’s Amperino® has been sold on a large scale for the treatment of autoimmune diseases, including rheumatoid arthritis, ankylosis, and psoriasis. The company plans to obtain approval for the biological analog of adalimumab——Anjianning® at the end of this year.

Founded in 2002, PAG (formerly known as Pacific Alliance Group) is one of the region’s largest Asia-focused investment managers with funds under management across Private Equity, Real Estate, and Absolute Return strategies. The company also creates funding and operational solutions for its investment partners and portfolio companies, across the capital structure and across Asia.

Its operations are supported by a robust infrastructure and commitment to best-in-class risk management, governance, and transparency.